Year-end Sale % OFF 
Abstract
ConclusionAlthough type 2 diabetic patients exhibit resistance to GIP when the peptide is administered in doses that result in circulating levels approximating those found physiologically, it is likely that DP IV-resistant forms of the peptide administered in pharmacological doses will prove to be effective in improving glucose tolerance. Additionally, in view of recent studies showing that GIP receptor knockout mice are resistant to diet induced obesity25, it is possible that GIP-antagonists will prove useful in obesity treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
